The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function

Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity

(2013) Xiaohua Zhang et al.   ANTI-CANCER DRUGS

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor

(2013) Matteo Santoni et al.   INTERNATIONAL JOURNAL OF CANCER

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors

(2013) Franziska Stehle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

(2012) Stefanie Andrea Erika Held et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression

(2012) J. C. Doloff et al.   CANCER RESEARCH

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model

(2012) Anamika Bose et al.   MELANOMA RESEARCH

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone

(2011) G. Kock et al.   BLOOD

Immunotherapy in renal cell carcinoma

(2010) Annkristin Heine et al.   Immunotherapy

Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

(2010) Susanne M Rittig et al.   MOLECULAR THERAPY

Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression

(2009) Benjamin Johnson et al.   CURRENT MOLECULAR MEDICINE

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells

(2008) Frank Grünebach et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY